Recent Advances in Immunotherapy in Metastatic NSCLC.

Recent Advances in Immunotherapy in Metastatic NSCLC.
复制标题

转移性NSCLC免疫疗法的最新进展。

DOI:
10.3389/fonc.2016.00239
复制
发表时间:
2016
影响因子:
4.7
通讯作者:
Boumber Y
Boumber Y
中科院分区:
医学3区
文献类型:
--
作者:
Bansal P;Osman D;Gan GN;Simon GR;Boumber Y

文献摘要

参考文献

被引文献

相似文献

非小细胞肺癌(NSCLC)是世界范围内最常见的恶性肿瘤之一,也是导致癌症死亡的主要原因。尽管靶向治疗取得了进展,但大多数非小细胞肺癌患者没有靶向的基因组改变。然而,最近发现NSCLC是一种免疫原性肿瘤类型,随着FDA最近批准编程死亡受体-1抑制剂,如nivolumab和pembrolizumab,免疫疗法的几项突破已导致NSCLC这一新治疗方式的迅速扩展。在这里,我们综述了转移性非小细胞肺癌的免疫治疗方法,包括检查点抑制剂,具有其他作用机制的药物,以及与其他药物的联合免疫治疗。随着免疫疗法的出现,转移性非小细胞肺癌的治疗选择正在迅速扩大,希望进一步延长转移性肺癌的预期寿命。
Non-small cell lung cancer (NSCLC) is one of most common malignancies and the leading cause of cancer deaths worldwide. Despite advances in targeted therapies, majority of NSCLC patients do not have targetable genomic alterations. Nevertheless, recent discovery that NSCLC is an immunogenic tumor type, and several breakthroughs in immunotherapies have led to rapid expansion of this new treatment modality in NSCLC with recent FDA approvals of programed death receptor-1 inhibitors, such as nivolumab and pembrolizumab. Here, we review promising immunotherapeutic approaches in metastatic NSCLC, including checkpoint inhibitors, agents with other mechanisms of action, and immunotherapy combinations with other drugs. With advent of immunotherapy, therapeutic options in metastatic NSCLC are rapidly expanding with the hope to further expand life expectancy in metastatic lung cancer.
DOI: 10.1038/ncomms10501
发表时间: 2016-02-17
影响因子: 16.6
作者:
Koyama S;Akbay EA;Li YY;Herter-Sprie GS;Buczkowski KA;Richards WG;Gandhi L;Redig AJ;Rodig SJ;Asahina H;Jones RE;Kulkarni MM;Kuraguchi M;Palakurthi S;Fecci PE;Johnson BE;Janne PA;Engelman JA;Gangadharan SP;Costa DB;Freeman GJ;Bueno R;Hodi FS;Dranoff G;Wong KK;Hammerman PS
通讯作者: Hammerman PS
DOI: 10.1200/edbook_am.2013.33.e295
发表时间: 2013-01-01
期刊: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
影响因子: --
作者:
Juergens, Rosalyn A;Rudin, Charles M
通讯作者: Rudin, Charles M
DOI: 10.4049/jimmunol.173.5.2985
发表时间: 2004-09-01
影响因子: 4.4
作者:
Chen, X;Doffek, K;Shilyansky, J
通讯作者: Shilyansky, J
DOI: 10.1093/annonc/mdv623
发表时间: 2016-04-01
期刊: ANNALS OF ONCOLOGY
影响因子: 50.5
作者:
Champiat, S.;Lambotte, O.;Marabelle, A.
通讯作者: Marabelle, A.
DOI: 10.1136/bmj.1.5023.841
发表时间: 1957-01-01
影响因子: 105.7
作者:
BURNET, M
通讯作者: BURNET, M